The way we’re treating cancer isn’t what it used to be. The landscape of personalized medicine is changing quickly, moving away from traditional chemotherapies and toward innovative new therapies such as antibody-drug conjugates or ADCs.
In the midst of a digital revolution, the medical field is experiencing a revolution of it’s own. The paradigm for which cancer is treated is evolving as novel drugs are being developed through a sharing of knowledge between chemical and biologic drug developers. These groundbreaking therapies provide a clear view into the exciting future of oncology and the development of the Next Generation Pharmaceuticals.
This promotional video – The Next Generation Pharmaceuticals – was produced by Lonza.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.